| Overview |
| bs-9506R |
| EPCR Polyclonal Antibody |
| WB, IHC-P, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human EPCR/CD201 |
| 1-100/238 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 10544 |
| Extracellular |
| Activated protein C receptor; APC receptor; APCR; CCCA; CCD41; CD201 antigen; centrocyclin; Endothelial cell protein C receptor; MGC23024; PROCR; EPCR_HUMAN; CD201. |
| EPCR is a receptor for activated protein C, a serine protease activated by and involved in the blood coagulation pathway. It is an N glycosylated type I membrane protein that enhances the activation of protein C. Mutations in this gene have been associated with venous thromboembolism and myocardial infarction, as well as with late fetal loss during pregnancy. It is expressed strongly in the endothelial cells of arteries and veins in heart and lung. It is overexpressed in several human non-Pgp multidrug resistant (MDR) tumor cell lines. Whether and how anti-coagulant and anti-inflammatory functions of EPCR facilitate oncogenesis and/or drug resistance is unclear. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz